Among many new STDs evolving globally, Herpes simplex type-1 and type-2 are still prominent in the world. According to WHO, most people carry this virus, and most of them don’t even know about it. However, this virus is growing globally, and it doesn’t seem that it’ll stop any time soon.
Both of these viruses cause blisters or sores around different areas of the body. Typically, HSV-1(oral herpes) causes blisters around a person’s mouth, whereas HSV-2 (genital herpes) causes blisters around the genital area of people. Most commonly, HSV-1 occurs in humans due to sharing of things, while sexual intercourse is the main reason for genital herpes.
Due to the evolution of sexual practices in humans, HSV-1 can also cause genital herpes through oral sex. For ages, it has been an incurable disease. Scientists are trying since the 1930s to develop an effective vaccine for curing it. However, there hasn’t been a progressive answer from their side. They have found treatments to reduce herpes’s breakouts, but there’s no word on the vaccine.
Vaccine Development to Combat HSV-1 and HSV-2
Recently, many new pharma companies like GlaxoSmithKline, Sanofi, and Vical Inc have developed some promising vaccine development. Moreover, some medical universities are also developing vaccines to eradicate HSV-1/2 from the world successfully. Besides, rational vaccines are also developing vaccines to eradicate this virus.
Rational vaccines develop vaccine candidates that are rationally engineered. Recently, they carried out an animal study in which they tested their two vaccine candidates, RVx201 and RVx202, on guinea pigs. After 28 days of observing the effect of the vaccines, the study established that all the pigs were perfectly fine at the end of the study and didn’t develop any HSV-associated disease.
This particular study supported that the vaccine candidates are safe and can be a potential vaccine for herpes.
Moreover, Rational vaccines also granted a license to the University of Louisiana for their work in developing herpes vaccine, which supports the ideology of Rational Vaccine. University developed a vaccine candidate, VC2, which has the potential of completely ending the Herpes disease.
VC2 vaccine primarily targets sores and diseases caused by HSV-1, and it can also protect against genital herpes caused by HSV-2. Moreover, VC2 shows promising results because it shows an impeccable growth in immune response in mice, protecting them from HSV diseases.
GSK has also been making great achievements in developing a vaccine for herpes. It has started the phase-1 study of its vaccine, which has four different doses level. Most commonly, healthy adults are the first priority for this vaccine. The completion time for the vaccine is estimated to be around August 2022.
University of Pennsylvania
A dedicated research time at the university is working to bring a vaccine for eradicating HSV successfully. It has found success with an mRNA vaccine approach, and the goal of the vaccine was to keep the virus inactive. In April, the CDC authorized the university and gave them a heads-on to continue with the research since the vaccine was successful in an animal study.
The benefit of mRNA technology is that patients gain protection without getting sick. And the antibody response was three times greater with this vaccine than with a protein-related vaccine.
Other Vaccine Candidates
Those mentioned above are the most recent updates regarding the vaccine market for herpes. Besides, many other companies are working on developing a new vaccine. NanoVax is another company developing a unique adjuvant vaccine. Similarly, Delta gD-2 is another vaccine candidate that has deleted the glycoprotein gD-2.
Many people who have the disease are beginning to adapt to it and consider it a normal thing. Vaccine development of HSV might take a lot of time, but patients can always make use of traditional curing methods to reduce the severity of the disease.